Search

Press Release & Announcements

 01 SEPTEMBER 2016

ASLAN Pharmaceuticals and A*STAR enter RON antibody licensing and research collaboration agreement 

ASLAN and A*STAR to collaborate on the development of RON antibody to advance the treatment of cancer types prevalent in Asia


01 AUGUST 2016

Skin Microbes Modulate Eczema Flared

Finding provides deeper understanding of the skin disease and could lead to possible interventions for improved skin health

Biomarkers & Stratified Medicine

  • Personalised OMIC Lattice for Advanced Research and Improving Stratification (POLARIS)

    POLARIS is a large clinical –omics project involving A*STAR researchers and clinical partners from the National Cancer Centre and National University Hospital (NUH). The POLARIS team aims to establish CAP-accredited biomarker validation laboratories for OMICS assays, with an initial focus on common Asian diseases such as lung cancer. By matching the right patient to the right drug at the right time, precision medicine can lead to better patient outcomes through improved clinical response rates and reduced treatment toxicities.

  • Companion Diagnostics Project

    The ETC- and D3-based Companion Diagnostics project aims to develop prognostic and predictive biomarkers for targeted treatment by leveraging Singapore’s strengths in research into gastric, liver and haematopoietic cancers.

Consumer Care

Singapore has built up foundational research in stem cells, tissue engineering and skin biology with a focus on Asian skin types. Thanks to our diverse multi-ethnic population, we  provide a valuable resource for companies seeking to understand a variety of the world’s skin types in a single location.

Singapore’s focus is to integrate and leverage engineering capabilities in materials, imaging, modelling and simulation to create and develop technologies that address the needs of Asian skin types and preferences. 

Skin Research Institute of Singapore (SRIS)

Jointly established by A*STAR, National Skin Centre and Nanyang Technological University, the Skin Research Institute of Singapore (SRIS) harnesses the expertise of scientists, clinicians and engineers to conduct high-impact, inter-disciplinary skin research designed to achieve improved health outcomes and quality of life. The Institute specialises in key research areas such as eczema, allergy and inflammation, pigmentary disorders, wound healing, hair conditions and skin ageing.

Drug Development Programmes

Drug Discovery & Development (D3) Programme

The D3 Programme facilitates the preclinical development of drug candidates and early clinical trials up to Proof-of-Concept in man. 

Projects undertaken by D3 include local drug candidates as well as assets in-licensed from biotechs and pharma multinational companies (MNCs).


Food and Nutrition

To facilitate new product development in the food and nutrition industry, a complex understanding of the human biology and an extensive knowledge in the integration of engineering solutions are key. With our deep understanding of the Asian phenotype and culture, we are able to innovate new foods that improve health and impact lifestyle choices as well as address Singapore’s food security needs.

Singapore Centre for Nutritional Sciences, Metabolic Diseases and Human Development (SiNMeD)

SiNMeD, a collaboration between Singapore Institute for Clinical Sciences (SICS) and the Yong Loo Lin School of Medicine, studies metabolic diseases, human development and nutritional sciences in Asian populations. Much of these studies are done in close collaboration with clinical partners such as KK Women’s and Children’s Hospital (KKH) and National University Hospital (NUH). 

SiNMeD’s key programmes include: 

  • Clinical Nutrition Research Centre (CNRC)

    The CNRC is a joint initiative between SICS and the National University Health System (NUHS) and specialises in basic and translational human nutrition research to investigate the impact of micro- and macro- nutrient intake on human physiology, including the role of food structure and diet on metabolic diseases. 

    The CNRC is one of the few nutritional centres in Asia that is fully equipped with state-of-the-art facilities to conduct clinical nutrition and whole body metabolism studies, using a whole body calorimeter. 

    For more details on the CNRC, visit here
  • Growing Up in Singapore Towards Healthy Outcomes (GUSTO)

    A joint programme between National University of Singapore (NUS), SICS and KKH, GUSTO is a birth cohort study that involves deep, longitudinal phenotyping of 1,200 mothers and their children from early pregnancy to early childhood. 

    The observational study is part of a worldwide academic consortium, EpiGen, which strives to advance understanding of the developmental and environmental processes that influence health through the course of life.

  • Asian Metabolic Phenotyping Singapore (AMPS)

    AMPS is a platform established by SICS, NUH and Singapore General Hospital (SGH) for conducting translational clinical research in metabolic diseases such as diabetes and obesity. It provides deep expertise in metabolic health, diagnostics, systems and molecular biology, as well as clinical imaging for intense phenotyping of adult subjects. AMPS also conducts studies that seek to understand the metabolic differences between the various ethnicities and how they respond physiologically to nutritional interventions.

  • Neurocognitive Development Centre (NDC)

    A nexus for interdisciplinary research on brain development and mental health, the NDC partners major international and local institutions to incorporate cognitive science and propose interventions suitable for public health practice. 

    The KKH-based centre emphasises evidence-based health care, and is actively involved in local and regional epidemiological studies that assess the molecular fundamentals of environmental influence on brain development, psychological health and function. 

 

The food and nutrition industry requires complex understanding of the human biology and an integration of engineering solutions to facilitate new product development. A*STAR’s research hinges on our deep understanding of the Asian phenotype and culture. This enables us to innovate new foods that improve health and impact lifestyle choices, as well as address Singapore’s food security needs.

  • Maternal & Infant Nutrition

    Growing Up in Singapore Towards healthy Outcomes (GUSTO) Clinical Study

    The GUSTO Clinical Study at SICS and local hospitals investigates how maternal diet and lifestyle during pregnancy influences child development in their first 18 months.

    EpiGen Consortium

    The EpiGen Consortium is an alliance of the world’s leading epigenetics and metabolic programming researchers from six research centres in Singapore, the UK and New Zealand.

  • Obesity & Type II Diabetes

    Singapore Adult Metabolism Study (SAMS)

    The SAMS is a clinical study conducted by SICS and local institutions that analyses ethnic differences among Indian, Chinese, and Malay populations in metabolic disease.

    Singapore Institute for Nutritional Sciences, Metabolic Diseases, and Human Development (SiNMeD)

    The SiNMeD is a joint centre between SICS and the Yong Loo Lin School of Medicine that studies metabolic diseases in Asian populations. 

    Clinical Nutrition Research Centre (CNRC)

    The CNRC, led by SICS and NUHS, conducts nutritional sciences research and studies development of obesity and diabetes in Asian populations. 

 

Medical Technology

Medical technology (MedTech) encompasses technologies such as devices and equipment as well as platforms that diagnose, treat and/or improve human health care. 

We’ve established several initiatives to nurture MedTech R&D and entrepreneurship in Singapore. These, together with our wide spectrum of capabilities in biomedical sciences, and physical sciences and engineering, have enabled us to collaborate in cross-disciplinary research with universities and hospitals as well as local and overseas industry partners. As a result, we have been able to contribute to the growth of a vibrant ecosystem for MedTech innovations. 

Our MedTech innovations span a wide range of medical applications:

 

Pharmaceuticals and Biologics (PharmBio)

The PharmBio cluster invests in and supports programmes that further our understanding of diseases. Using this knowledge, we create novel treatments that:

  • maximise research value
  • create jobs 
  • attract private R&D investments into Singapore 

Working closely with clinical and engineering research partners, we focus on the following three areas:

  1. Drug Discovery and Development
  2. Deep Genotypic and/or Phenotypic Studies of Diseases
  3. Biomanufacturing